Search

Your search keyword '"Weinshenker, Brian G."' showing total 1,108 results
Start Over Author "Weinshenker, Brian G."
1,108 results on '"Weinshenker, Brian G."'

201. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody

Author

Dubey, Divyanshu, primary, Pittock, Sean J., additional, Krecke, Karl N., additional, Morris, Padraig P., additional, Sechi, Elia, additional, Zalewski, Nicholas L., additional, Weinshenker, Brian G., additional, Shosha, Eslam, additional, Lucchinetti, Claudia F., additional, Fryer, James P., additional, Lopez-Chiriboga, A. Sebastian, additional, Chen, John C., additional, Jitprapaikulsan, Jiraporn, additional, McKeon, Andrew, additional, Gadoth, Avi, additional, Keegan, B. Mark, additional, Tillema, Jan-Mendelt, additional, Naddaf, Elie, additional, Patterson, Marc C., additional, Messacar, Kevin, additional, Tyler, Kenneth L., additional, and Flanagan, Eoin P., additional

Published
2019
Full Text
View/download PDF

202. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Author

Ciccarelli, Olga, primary, Cohen, Jeffrey A, additional, Reingold, Stephen C, additional, Weinshenker, Brian G, additional, Amato, Maria Pia, additional, Banwell, Brenda, additional, Barkhof, Frederik, additional, Bebo, Bruce, additional, Becher, Burkhard, additional, Bethoux, François, additional, Brandt, Alexander, additional, Brownlee, Wallace, additional, Calabresi, Peter, additional, Chatway, Jeremy, additional, Chien, Claudia, additional, Chitnis, Tanuja, additional, Ciccarelli, Olga, additional, Cohen, Jeffrey, additional, Comi, Giancarlo, additional, Correale, Jorge, additional, De Sèze, Jerome, additional, De Stefano, Nicola, additional, Fazekas, Franz, additional, Flanagan, Eoin, additional, Freedman, Mark, additional, Fujihara, Kazuo, additional, Galetta, Steven, additional, Goldman, Myla, additional, Greenberg, Benjamin, additional, Hartung, Hans-Peter, additional, Hemmer, Bernhard, additional, Henning, Anke, additional, Izbudak, Izlem, additional, Kappos, Ludwig, additional, Lassmann, Hans, additional, Laule, Cornelia, additional, Levy, Michael, additional, Lublin, Fred, additional, Lucchinetti, Claudia, additional, Lukas, Carsten, additional, Marrie, Ruth Ann, additional, Miller, Aaron, additional, Miller, David, additional, Montalban, Xavier, additional, Mowry, Ellen, additional, Ourselin, Sebastien, additional, Paul, Friedemann, additional, Pelletier, Daniel, additional, Ranjeva, Jean-Philippe, additional, Reich, Daniel, additional, Reingold, Stephen, additional, Rocca, Maria Assunta, additional, Rovira, Alex, additional, Schlaerger, Regina, additional, Soelberg Sorensen, Per, additional, Sormani, Maria, additional, Stuve, Olaf, additional, Thompson, Alan, additional, Tintoré, Mar, additional, Traboulsee, Anthony, additional, Trapp, Bruce, additional, Trojano, Maria, additional, Uitdehaag, Bernard, additional, Vukusic, Sandra, additional, Waubant, Emmanuelle, additional, Weinshenker, Brian, additional, Wheeler-Kingshott, Claudia Gandini, additional, and Xu, Junqian, additional

Published
2019
Full Text
View/download PDF

203. Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria

Author

Zalewski, Nicholas L., primary, Rabinstein, Alejandro A., additional, Krecke, Karl N., additional, Brown, Robert D., additional, Wijdicks, Eelco F. M., additional, Weinshenker, Brian G., additional, Kaufmann, Timothy J., additional, Morris, Jonathan M., additional, Aksamit, Allen J., additional, Bartleson, J. D., additional, Lanzino, Giuseppe, additional, Blessing, Melissa M., additional, and Flanagan, Eoin P., additional

Published
2019
Full Text
View/download PDF

204. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.

Author

Sechi, Elia, Krecke, Karl N, Pittock, Sean J, Dubey, Divyanshu, Lopez-Chiriboga, A Sebastian, Kunchok, Amy, Weinshenker, Brian G, Zalewski, Nicholas L, and Flanagan, Eoin P

Subjects
MYELIN oligodendrocyte glycoprotein, MYELITIS, NEUROGENIC bladder, TRANSVERSE myelitis, AUTOANTIBODIES, SPINAL cord, DISABILITIES
Abstract

Background: Myelitis accompanied by a negative spinal cord MRI may lead to diagnostic uncertainty. Objective and Methods: We retrospectively investigated the frequency of negative spinal cord MRI (performed <6 weeks from onset) in Mayo Clinic patients with myelin oligodendrocyte glycoprotein (MOG)-IgG-associated myelitis (2000–2019). Results: The initial spinal cord MRI was negative in 7/73 (10%) patients, despite severe acute disability (median EDSS, 7 (range, 4.5–8)); myelitis symptoms/signs were frequent (paraparesis, neurogenic bladder, sensory level, Lhermitte's phenomenon). Myelitis lesions became overt at follow-up MRI in three patients. Conclusions: A negative spinal cord MRI should not dissuade from MOG-IgG testing in patients with acute/subacute myelitis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

208. Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis

Author

Sechi, Elia, primary, Morris, P Pearse, additional, McKeon, Andrew, additional, Pittock, Sean J, additional, Hinson, Shannon R, additional, Weinshenker, Brian G, additional, Aksamit, Allen J, additional, Krecke, Karl N, additional, Kaufmann, Timothy J, additional, Jolliffe, Evan A, additional, Zalewski, Nicholas L, additional, Zekeridou, Anastasia, additional, Wingerchuk, Dean M, additional, Jitprapaikulsan, Jiraporn, additional, and Flanagan, Eoin P, additional

Published
2018
Full Text
View/download PDF

210. Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria

Author

Thompson, Alan J, Banwell, Brenda L, Barkhof, Frederik, Carroll, William M, Coetzee, Timothy, Comi, Giancarlo, Correale, Jorge, Fazekas, Franz, Filippi, Massimo, Freedman, Mark S, Fujihara, Kazuo, Galetta, Steven L, Hartung, Hans Peter, Kappos, Ludwig, Lublin, Fred D, Marrie, Ruth Ann, Miller, Aaron E, Miller, David H, Montalban, Xavier, Mowry, Ellen M, Sorensen, Per Soelberg, Tintoré, Mar, Traboulsee, Anthony L, Trojano, Maria, Uitdehaag, Bernard M J, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian G, Reingold, Stephen C, Cohen, Jeffrey A, Thompson, Alan J, Banwell, Brenda L, Barkhof, Frederik, Carroll, William M, Coetzee, Timothy, Comi, Giancarlo, Correale, Jorge, Fazekas, Franz, Filippi, Massimo, Freedman, Mark S, Fujihara, Kazuo, Galetta, Steven L, Hartung, Hans Peter, Kappos, Ludwig, Lublin, Fred D, Marrie, Ruth Ann, Miller, Aaron E, Miller, David H, Montalban, Xavier, Mowry, Ellen M, Sorensen, Per Soelberg, Tintoré, Mar, Traboulsee, Anthony L, Trojano, Maria, Uitdehaag, Bernard M J, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian G, Reingold, Stephen C, and Cohen, Jeffrey A

Abstract

The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years suggest that they might no longer provide the most up-to-date guidance for clinicians and researchers. The International Panel on Diagnosis of Multiple Sclerosis reviewed the 2010 McDonald criteria and recommended revisions. The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation. The following changes were made: in patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis of multiple sclerosis; symptomatic lesions can be used to demonstrate dissemination in space or time in patients with supratentorial, infratentorial, or spinal cord syndrome; and cortical lesions can be used to demonstrate dissemination in space. Research to further refine the criteria should focus on optic nerve involvement, validation in diverse populations, and incorporation of advanced imaging, neurophysiological, and body fluid markers.

Published
2018

216. Elsberg syndrome

Author

Savoldi, Filippo, primary, Kaufmann, Timothy J., additional, Flanagan, Eoin P., additional, Toledano, Michel, additional, and Weinshenker, Brian G., additional

Published
2017
Full Text
View/download PDF

218. Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder

Author

Asgari, Nasrin, primary, Flanagan, Eoin P., additional, Fujihara, Kazuo, additional, Kim, Ho Jin, additional, Skejoe, Hanne P., additional, Wuerfel, Jens, additional, Kuroda, Hiroshi, additional, Kim, Su Hyun, additional, Maillart, Elisabeth, additional, Marignier, Romain, additional, Pittock, Sean J., additional, Paul, Friedemann, additional, and Weinshenker, Brian G., additional

Published
2017
Full Text
View/download PDF

221. Challenges and opportunities in designing clinical trials for neuromyelitis optica

Author

Weinshenker, Brian G, Barron, Gerard, Behne, Jacinta M, Bennett, Jeffery L, Chin, Peter S, Cree, Bruce AC, de Seze, Jerome, Flor, Armando, Fujihara, Kazuo, Greenberg, Benjamin, Higashi, Sayumi, Holt, William, Khan, Omar, Knappertz, Volker, Levy, Michael, Melia, Angela T, Palace, Jacqueline, Smith, Terry J, Sormani, Maria Pia, Van Herle, Katja, VanMeter, Susan, Villoslada, Pablo, Walton, Marc K, Wasiewski, Warren, Wingerchuk, Dean M, Yeaman, Michael R, and Guthy-Jackson Charitable Foundation International Clinical Consortium

Subjects
Clinical Trials as Topic, Neurology & Neurosurgery, Research Design, Clinical Research, Neuromyelitis Optica, Clinical Sciences, Neurosciences, Humans, Cognitive Sciences, Eye Disease and Disorders of Vision, Guthy-Jackson Charitable Foundation International Clinical Consortium
Abstract

Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of NMO has impeded clinical trials for this disease. However, a diagnostic biomarker and recognition of a wider spectrum of NMO presentations has expanded the patient population from which study candidates might be recruited. Emerging insights into the pathogenesis of NMO have provided rationale for exploring new therapeutic targets. Academic, pharmaceutical, and regulatory communities are increasingly interested in meeting the unmet needs of patients with NMO. Clinical trials powered to yield unambiguous outcomes and designed to facilitate rapid evaluation of an expanding pipeline of experimental agents are needed. NMO-related disability occurs incrementally as a result of attacks; thus, limiting attack frequency and severity are critical treatment goals. Yet, the severity of NMO and perception that currently available agents are effective pose challenges to study design. We propose strategies for NMO clinical trials to evaluate agents targeting recovery from acute attacks and prevention of relapses, the 2 primary goals of NMO treatment. Aligning the interests of all stakeholders is an essential step to this end.

Published
2015

226. Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.

Author

Toledano, Michel, Weinshenker, Brian G., Kaufmann, Timothy J., Parisi, Joseph E., and Paz Soldán, M. Mateo

Subjects
*HYPOTHERMIA, *MULTIPLE sclerosis, *DEMOGRAPHY, *MAGNETIC resonance imaging
Abstract

Background: Episodic hypothermia (EH) can occur in multiple sclerosis (MS). The putative mechanism is impairment of thermoregulation due to a presumed demyelinating hypothalamic lesion. Objective: To describe a cohort of patients with MS, who developed EH. Methods: Patients were identified through review of the Mayo Clinic electronic medical record (1996 to July 2015). Search terms were [multiple sclerosis] or [MS] within the diagnoses field and [hypothermia] within any field. We reviewed records for accuracy of diagnoses and abstracted relevant data. Magnetic resonance imaging (MRI) was reviewed for presence of hypothalamic lesions. Results: Of 156 patients, 34 had concurrent MS and hypothermia. Thirty-two (94%) had progressive disease at EH onset. Median MS duration was 19.9 years, and median expanded disability status scale (EDSS) was 8.0. Most patients presented with alterations in consciousness. Infection was suspected as the precipitating factor in 19 (56%), but clinically/laboratory supported in only 9 (28%). MRI lesions were evident within the hypothalamus in only 4 (14%). Conclusion: EH occurs predominantly in patients with advanced secondary progressive MS. The major manifestation is altered consciousness. Infection is often suspected as causal, but infrequently confirmed. Although commonly implicated, hypothalamic lesions were rarely evident on MRI and were absent in two post-mortem evaluations. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

228. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum

Author

Flanagan, Eoin P., Weinshenker, Brian G., Krecke, Karl N., Lennon, Vanda A., Lucchinetti, Claudia F., McKeon, Andrew, Wingerchuk, Dean M., Shuster, Elizabeth A., Jiao, Yujuan, Horta, Erika S., and Pittock, Sean J.

Subjects
Adult, Aquaporin 4, Male, Neuromyelitis Optica, Middle Aged, Myelitis, Magnetic Resonance Imaging, Article, Statistics, Nonparametric, Spinal Cord, Immunoglobulin G, Humans, Female, Longitudinal Studies, Aged
Abstract

Short transverse myelitis (STM;3 vertebral segments) is considered noncharacteristic of neuromyelitis optica (NMO) spectrum disorders (NMOSDs). Nonappreciation of the potential for STM to occur in NMOSD may lead to increased disability from delay in diagnosis and appropriate treatment.To determine the frequency of short lesions at the initial myelitis manifestation of NMOSD and to compare the demographic, clinical, and radiological characteristics of aquaporin-4-IgG (AQP4-IgG) seropositive and seronegative STM.We reviewed the records and images of patients at the Mayo Clinic who were identified as AQP4-IgG positive from 1996 to 2014. Inclusion criteria were first STM episode, magnetic resonance imaging performed 90 days or less from symptom onset, spinal cord T2-hyperintense lesion less than 3 vertebral segments, AQP4-IgG seropositivity, and a final diagnosis of NMO or NMOSD. Patients with an initial longitudinally extensive transverse myelitis were excluded (n = 151). Patients with STM who were seronegative for AQP4-IgG among an Olmsted County population-based cohort of inflammatory demyelinating disorders of the central nervous system were used as a control group.Delay to diagnosis in months, clinical and radiological characteristics, and disability measured by ambulatory status.Twenty-five patients who were AQP4-IgG seropositive with an initial STM represented 14% of initial myelitis episodes among patients with NMOSD. The STM episode was defined as the first manifestation of NMOSD in 10 patients (40%) preceded by optic neuritis in 13 patients (52%) and preceded by a nausea and vomiting episode in 2 patients (8%). In comparison with the excluded patients with NMOSD who had an initial longitudinally extensive transverse myelitis, delay to diagnosis/treatment was greater when initial lesions were short (P = .02). In AQP4-IgG-positive STM cases, subsequent myelitis episodes were longitudinally extensive in 92%. Attributes more common in patients with AQP4-IgG-positive STM than in 27 population-based patients with AQP4-IgG-negative STM included the following: nonwhite race/ethnicity; tonic spasms; coexisting autoimmunity; magnetic resonance imaging (central cord lesions, T1 hypointensity, and a brain inconsistent with multiple sclerosis); and cerebrospinal fluid (oligoclonal bands lacking).Short transverse myelitis is not uncommon in NMOSD and, when it is present, delays diagnosis and treatment. Clinical and radiological characteristics identified in this study may help select patients with STM who are at the highest risk for an NMOSD. Short transverse myelitis does not exclude consideration of AQP4-IgG testing or NMOSD diagnosis.

Published
2015

232. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients

Author

Flanagan, Eoin P., primary, Hinson, Shannon R., additional, Lennon, Vanda A., additional, Fang, Boyan, additional, Aksamit, Allen J., additional, Morris, P. Pearse, additional, Basal, Eati, additional, Honorat, Josephe A., additional, Alfugham, Nora B., additional, Linnoila, Jenny J., additional, Weinshenker, Brian G., additional, Pittock, Sean J., additional, and McKeon, Andrew, additional

Published
2017
Full Text
View/download PDF

234. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders

Author

Zalewski, Nicholas L, primary, Morris, Padraig P, additional, Weinshenker, Brian G, additional, Lucchinetti, Claudia F, additional, Guo, Yong, additional, Pittock, Sean J, additional, Krecke, Karl N, additional, Kaufmann, Timothy J, additional, Wingerchuk, Dean M, additional, Kumar, Neeraj, additional, and Flanagan, Eoin P, additional

Published
2016
Full Text
View/download PDF

235. Progressive solitary sclerosis

Author

Keegan, B. Mark, primary, Kaufmann, Timothy J., additional, Weinshenker, Brian G., additional, Kantarci, Orhun H., additional, Schmalstieg, William F., additional, Paz Soldan, M. Mateo, additional, and Flanagan, Eoin P., additional

Published
2016
Full Text
View/download PDF

237. The contemporary spectrum of multiple sclerosis misdiagnosis

Author

Solomon, Andrew J., primary, Bourdette, Dennis N., additional, Cross, Anne H., additional, Applebee, Angela, additional, Skidd, Philip M., additional, Howard, Diantha B., additional, Spain, Rebecca I., additional, Cameron, Michelle H., additional, Kim, Edward, additional, Mass, Michele K., additional, Yadav, Vijayshree, additional, Whitham, Ruth H., additional, Longbrake, Erin E., additional, Naismith, Robert T., additional, Wu, Gregory F., additional, Parks, Becky J., additional, Wingerchuk, Dean M., additional, Rabin, Brian L., additional, Toledano, Michel, additional, Tobin, W. Oliver, additional, Kantarci, Orhun H., additional, Carter, Jonathan L., additional, Keegan, B. Mark, additional, and Weinshenker, Brian G., additional

Published
2016
Full Text
View/download PDF

241. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls

Author

Chen, Jun, primary, Chia, Nicholas, additional, Kalari, Krishna R., additional, Yao, Janet Z., additional, Novotna, Martina, additional, Paz Soldan, M. Mateo, additional, Luckey, David H., additional, Marietta, Eric V., additional, Jeraldo, Patricio R., additional, Chen, Xianfeng, additional, Weinshenker, Brian G., additional, Rodriguez, Moses, additional, Kantarci, Orhun H., additional, Nelson, Heidi, additional, Murray, Joseph A., additional, and Mangalam, Ashutosh K., additional

Published
2016
Full Text
View/download PDF

242. Gut microbiota dysbiosis in patients with Multiple Sclerosis

Author

Mangalam, Ashutosh K, primary, Chia, Nicholas, additional, Chen, Jun, additional, Kalari, Krishna R, additional, Yao, Janet Z, additional, Novotna, Martina, additional, Soldan, Mateo Paz, additional, Luckey, David, additional, Marietta, Eric V, additional, Jeraldo, Patricio R, additional, Chen, Xianfeng, additional, Weinshenker, Brian G, additional, Rodriguez, Moses, additional, Kantarci, Orhun H, additional, Nelson, Heidi, additional, and Murray, Joseph A, additional

Published
2016
Full Text
View/download PDF

243. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum

Author

Flanagan, Eoin P., primary, Cabre, Philippe, additional, Weinshenker, Brian G., additional, Sauver, Jennifer St, additional, Jacobson, Debra J., additional, Majed, Masoud, additional, Lennon, Vanda A., additional, Lucchinetti, Claudia F., additional, McKeon, Andrew, additional, Matiello, Marcelo, additional, Kale, Nilifur, additional, Wingerchuk, Dean M., additional, Mandrekar, Jay, additional, Sagen, Jessica A., additional, Fryer, James P., additional, Robinson, Angala Borders, additional, and Pittock, Sean J., additional

Published
2016
Full Text
View/download PDF

244. Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody-Positive Meningoencephalitis.

Author

Chen, John J., Aksamit, Allen J., McKeon, Andrew, Pittock, Sean J., Weinshenker, Brian G., Leavitt, Jacqueline A., Morris, Padraig P., and Flanagan, Eoin P.

Abstract

Background: Glial fibrillary acidic protein (GFAP) autoantibody-positive meningoencephalitis is a newly described entity characterized by a corticosteroid-responsive meningoencephalomyelitis. Some patients with GFAP autoantibody-positive meningoencephalitis have been found to have optic disc edema, which has previously not been well characterized. Methods: We performed a retrospective, observational case series of Mayo Clinic patients found to have GFAP-IgG and optic disc edema from January 1, 2000, to December 31, 2016. We identified 40 patients with GFAP-IgG seropositivity by tissue-based immunofluorescence and cell-based assay. Patients were screened for the following inclusion criteria: 1) serum, cerebrospinal fluid, or both that yielded a characteristic astrocytic pattern of mouse tissue immunostaining with confirmation of IgG reactive with specific GFAPa isoform by cell-based assay; 2) meningoencephalitis or encephalitis; and 3) optic disc edema. We excluded those with coexisting aquaporin-4-IgG or insufficient clinical information. Results: Ten patients had optic disc edema and met inclusion criteria. The median age was 39.5 years and 60% were men. Visual acuity was unaffected and disc edema was bilateral in all cases. Mild vitreous cell was noted in 3 patients. The optic disc edema resolved with corticosteroid treatment but resulted in mild optic atrophy in 2 patients. The median lumbar puncture opening pressure was 144 mm H2O (range, 84-298 mm H2O). Brain MRI revealed radial perivascular enhancement in all except 1 patient. Fluorescein angiography was available for 1 patient with optic disc edema, which showed leakage from the venules. Conclusions: Patients with GFAP autoantibody-positive meningoencephalitis can have optic disc edema that can mimic papilledema. The cause of the optic disc edema remains uncertain, but most patients did not have raised intracranial pressure. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

246. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Author

Cree, Bruce A C, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean M, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas, Orhan, Hartung, Hans-Peter, Lublin, Fred D, Drappa, Jorn, Barron, Gerard, Madani, Soraya, Ratchford, John N, She, Dewei, Cimbora, Daniel, and Katz, Eliezer

Abstract

No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes blindness and paralysis. We aimed to assess the efficacy and safety of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD.

Published
2019
Full Text
View/download PDF

247. McArdle Sign: A Specific Sign of Multiple Sclerosis

Author

Savoldi, Filippo, Nasr, Zahra, Hu, Wei, Schilaty, Nathan D., Delgado, Adriana M., Mandrekar, Jay, Kaufman, Kenton R., Berglund, Lawrence, and Weinshenker, Brian G.

Abstract

To measure McArdle sign (rapidly reversible weakness induced by neck flexion) both qualitatively and quantitatively and to evaluate its specificity and clinical utility for diagnosis of multiple sclerosis (MS).

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results